Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer

This is an interventional study in 20 patients with resectable non-small cell lung cancer who will receive 2 courses of durvalumab (MEDI4736) in the neo-adjuvant setting, followed by surgery with curative intent. Experimental imaging procedures include 1) Zr-89-labelled durvalumab (MEDI4736) scan prior to neo-adjuvant treatment to determine accessibility and intra-tumoral distribution of durvalumab (MEDI4736) and 2) (first cohort) injection of ex vivo \[111In\]-oxine labelled autologous CD8+ T-cells 48 hours prior to surgery, or (second cohort) injection of \[89Zr\]-Df-crefmirlimab prior to surgery. The scan is scheduled on the day of surgery and after surgery, the resected tumor specimen with ex vivo \[111In\]-oxine labelled or in vivo \[89Zr\]-Df-crefmirlimab labelled CD8+ T-cells in situ, is fixated for high-resolution ex vivo imaging on a preclinical U-SPECT scanner and quantitative histopathological analysis, next to standard histopathological evaluation. Total duration of the study is maximum 42 days (from injection therapeutic dose durvalumab (MEDI4736) to surgery).